HTTIF (HighTide Therapeutics) Total Debt per Share: $0.04 (As of Dec. 2025)


HTTIF HighTide Therapeutics Inc HTTIF
14 GF Score
Price $0.39
! 3 Warning Signs
View Full Analysis

What is HighTide Therapeutics Total Debt per Share?

HighTide Therapeutics HTTIF 14 Total Debt per Share is $0.04 as of Dec. 2025. GuruFocus rates HTTIF with a GF Score™ of 14/100. The stock has 3 warning signs investors should review.

$0.04 (As of Dec. 2025)

Total Debt per Share is calculated as total debt divided by Shares Outstanding (EOP). Total debt is calculated as Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. HighTide Therapeutics's Total Debt Per Share for the quarter that ended in Dec. 2025 was $0.04.

HighTide Therapeutics Total Debt per Share Historical Data

* Premium members only.

The historical data trend for HighTide Therapeutics's Total Debt per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

HighTide Therapeutics Total Debt per Share Chart

HighTide Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Total Debt per Share
0.00 0.01 0.00 0.02 0.04

HighTide Therapeutics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Debt per Share Get a 7-Day Free Trial Premium Member Only 0.00 0.01 0.02 0.03 0.04
HTTIF
14GF Score
HighTide Therapeutics Inc HTTIF
Total Debt per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

HighTide Therapeutics Total Debt per Share Calculation

HighTide Therapeutics's Total Debt Per Share for the fiscal year that ended in Dec. 2025 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(12.52+5.49)/508.72
=0.04

HighTide Therapeutics's Total Debt Per Share for the quarter that ended in Dec. 2025 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(12.52+5.49)/508.72
=0.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Debt per Share →
What does a Total Debt per Share of $0.04 mean?
HighTide Therapeutics (HTTIF) has a Total Debt per Share of $0.04 as of Dec. 2025. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on HighTide Therapeutics and its competitors.
Is HighTide Therapeutics' Total Debt per Share too high?
HighTide Therapeutics' current Total Debt per Share is $0.04. Overall, HighTide Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does HighTide Therapeutics' Total Debt per Share compare to VRTX and REGN?
HighTide Therapeutics' Total Debt per Share of $0.04 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Debt per Share for a Biotechnology company?
A good Total Debt per Share depends on the Biotechnology industry context. However, Total Debt per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Debt per Share mean?
A high Total Debt per Share can signal that a stock is expensive relative to its fundamentals. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on HighTide Therapeutics and its competitors. HighTide Therapeutics's current Total Debt per Share is $0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HighTide Therapeutics stock overvalued right now?
HighTide Therapeutics (HTTIF) has a current Total Debt per Share of $0.04. The current Total Debt per Share is $0.04. HighTide Therapeutics' overall GF Score™ is 14/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Debt per Share calculated?
Total Debt per Share is calculated from a company's financial statements. For HighTide Therapeutics (HTTIF), the current Total Debt per Share is $0.04 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

HighTide Therapeutics Business Description

Other Exchanges 02511:Hong Kong
Address Fubao Street, 9th to 10th Floor, Building D, Shenfang Park, Futian District, Shenzhen-Hong Kong Science and, Technology Innovation Cooperation Zone, Guangdong, Shenzhen, CHN, 518112
HighTide Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of first-in-class multifunctional, multi-targeted therapies for cardiovascular-kidney-metabolic (CKM) diseases and related metabolic disorders. The company is developing a pipeline of proprietary drug candidates targeting indications including type 2 diabetes mellitus, chronic kidney disease, obesity, metabolic dysfunction-associated steatohepatitis (MASH), and primary sclerosing cholangitis (PSC). Its core product candidate, HTD1801 (berberine ursodeoxycholate), is an orally delivered first-in-class anti-inflammatory metabolic modulator designed to target dual pathways involving AMPK activation and NLRP3 inflammasome inhibition.
14GF Score

Get the complete analysis for HTTIF

Total Debt per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.39
Price